CGT Global Taps Policy Architect to Solve Gene Therapy's Payment Puzzle

RENO, Nev. – April 30, 2026 – In a move that signals a critical shift in the cell and gene therapy (CGT) landscape, accelerator firm CGT Global has appointed Charlotte Ivancic, a veteran healthcare policy strategist, to its Board of Advisors. The appointment underscores a growing industry consensus: the greatest hurdles for revolutionary new medicines are no longer confined to the lab but lie within the complex corridors of policy, regulation, and reimbursement.

Ms. Ivancic’s appointment brings more than 25 years of high-level experience in federal health policy and legislative strategy to the Reno-based company. While CGT Global focuses on accelerating the innovation and implementation of advanced therapies, this move strategically fortifies its ability to tackle the immense financial and logistical barriers that prevent these treatments from reaching patients.

The Architect of Access

Charlotte Ivancic is not a typical board appointee. Her career is a roadmap of navigating and reshaping America's most complex healthcare payment systems. As a senior advisor to congressional leaders like Senate Majority Leader Bill Frist, House Budget Chairman Paul Ryan, and Speaker John Boehner, she was instrumental in shaping foundational healthcare legislation.

Her most notable achievement was leading the charge to repeal and replace Medicare's dysfunctional Sustainable Growth Rate (SGR) physician payment formula—a legislative feat that had eluded Congress for over a decade. By replacing a flawed system with one designed to reward quality and value, Ivancic proved her ability to broker consensus and execute fundamental reform within a deeply entrenched federal bureaucracy. It is this specific expertise—dismantling unworkable payment models and building sustainable frameworks—that CGT Global is betting on.

“Charlotte brings a rare combination of policy expertise and real-world impact,” said Cate Spears, Founder and CEO of CGT Global, in a statement. “She has helped shape the very reimbursement frameworks that now influence how advanced therapies can scale. As our industry works to reduce cost and expand access, her insight into Medicare, Medicaid, and federal policy will be critical in helping us translate innovation into sustainable care delivery.”

Navigating the Reimbursement Labyrinth

The need for such expertise has never been more acute. Cell and gene therapies, with their potential to offer one-time cures for devastating genetic diseases and cancers, carry price tags that can run into the millions of dollars per patient. These high upfront costs clash with a healthcare payment system designed for chronic, incremental treatments.

Payers, including Medicare, Medicaid, and private insurers, struggle to budget for these therapies. The challenges are numerous:

• Payment Misalignment: Inpatient treatments like CAR-T cell therapies are often reimbursed through Medicare's diagnosis-related group (DRG) system, which has historically failed to cover the full, multi-hundred-thousand-dollar cost of the therapy and its administration.

• Long-Term Value Uncertainty: Payers are hesitant to cover a multi-million dollar treatment without long-term data guaranteeing its durability, creating a risk-assessment stalemate that delays patient access.

• Access Delays: State Medicaid programs, which cover a significant portion of eligible patients for conditions like sickle cell disease, often have complex and slow coverage determination processes, with some reports indicating delays of up to 18 months post-FDA approval.

To address this, the industry is moving toward innovative solutions like value-based payment (VBP) models, where payment is tied to patient outcomes. The federal government is also stepping in, with the Centers for Medicare & Medicaid Services (CMS) launching its Cell and Gene Therapy Access Model in 2025 to test outcomes-based agreements for Medicaid. Ivancic’s deep understanding of these systems positions CGT Global to not only navigate but also help shape these emerging frameworks.

Beyond the Lab: A New Model for Delivery

CGT Global distinguishes itself from traditional contract development and manufacturing organizations (CDMOs) like Lonza or Catalent by adopting a broader “accelerator” model. The company's mission extends beyond manufacturing support to actively building the infrastructure needed for widespread patient access.

A key part of this strategy is advancing new outpatient care delivery models. Currently, many advanced therapies are administered exclusively at a handful of elite, centralized academic medical centers, requiring patients and their families to relocate for weeks or months. This creates immense financial and logistical burdens, severely limiting access.

By developing protocols and infrastructure for safe and effective outpatient administration, CGT Global aims to decentralize care, reduce costs associated with lengthy hospital stays, and improve the patient experience. This operational focus, combined with Ivancic’s policy acumen, creates a powerful two-pronged approach to breaking down barriers.

A Strategic Play for the Future of Medicine

The appointment of Charlotte Ivancic is more than a personnel announcement; it is a clear indicator of the maturation of the entire cell and gene therapy sector. The era of focusing solely on scientific breakthroughs is giving way to a new phase where commercial viability and systemic integration are paramount.

“Cell and gene therapies hold enormous promise, but realizing that promise requires more than scientific advancement,” Ivancic stated. “It requires thoughtful integration into the healthcare system addressing reimbursement, delivery models, and regulatory process. CGT Global is uniquely positioned to address these challenges, and I’m excited to support their mission to expand patient access.”

By bringing a master policy architect onto its advisory board, CGT Global is making a strategic declaration that the future of medicine will be built not only in the laboratory but also in the legislative and regulatory arenas where access is defined and value is determined. This move signals a proactive effort to build the bridges that will allow today's most advanced scientific discoveries to become tomorrow's standard of care for patients everywhere.